Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data

(2021) Antonia M. Joussen et al.   EYE

Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes

(2020) Thomas A Ciulla et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)

(2020) Adam R. Glassman et al.   OPHTHALMOLOGY

Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients’ persistence

(2020) Ingo Volkmann et al.   BMC Ophthalmology

THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES

(2020) Jeffrey S. Heier et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

(2019) Jayashree Sahni et al.   OPHTHALMOLOGY

Randomized Trial of Treat & Extend Ranibizumab With & Without Navigated Laser versus Monthly Dosing for DME: TREX-DME 2 Year Outcomes

(2019) John F. Payne et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Diabetic Retinopathy Preferred Practice Pattern®

(2019) Christina J. Flaxel et al.   OPHTHALMOLOGY

Mechanisms of macular edema: Beyond the surface

(2018) Alejandra Daruich et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Therapeutic targeting of the angiopoietin–TIE pathway

(2017) Pipsa Saharinen et al.   NATURE REVIEWS DRUG DISCOVERY

Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis

(2017) Seth R Flaxman et al.   Lancet Global Health

Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature

(2016) Mohammed Ashraf et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

(2016) Jörg T Regula et al.   EMBO Molecular Medicine

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

(2015) Christian Prünte et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Intravitreal Aflibercept for Diabetic Macular Edema

(2015) David M. Brown et al.   OPHTHALMOLOGY

TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES

(2015) K. Bailey Freund et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Ranibizumab for Diabetic Macular Edema

(2012) Quan Dong Nguyen et al.   OPHTHALMOLOGY

Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests

(2011) Frank Bretz et al.   BIOMETRICAL JOURNAL

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

(2010) Michael J. Elman et al.   OPHTHALMOLOGY

Association of Vitreous Inflammatory Factors with Diabetic Macular Edema

(2008) Hideharu Funatsu et al.   OPHTHALMOLOGY